Exposure to Gas, Dust, Fumes Ups Risk of Mite Sensitization

This article originally appeared here.
Share this content:
Exposure to Gas, Dust, Fumes Ups Risk of Mite Sensitization
Exposure to Gas, Dust, Fumes Ups Risk of Mite Sensitization

FRIDAY, Feb. 13, 2015 (HealthDay News) -- Occupational exposure to gas, dust, and fumes (GDF) increases the risk of mite sensitization, and is associated with asthma and wheeze in those who are mite-sensitized, according to a study published online Jan. 30 in Allergy.

Anders Bjerg, M.D., Ph.D., from the University of Gothenburg in Sweden, and colleagues examined the role of sensitization in the correlation between GDF and allergic conditions. Data were collected from questionnaires and skin prick tests from a population-based sample of 788 adults from the West Sweden Asthma Study.

The researchers found that GDF exposure correlated with a doubled risk of sensitization to mites, but not other allergens, after adjustment for confounders. The effect of GDF on asthma was modified by mite sensitization. GDF correlated with physician-diagnosed asthma and wheeze in mite-sensitized subjects (adjusted odds ratios, 2.9 [95 percent confidence interval, 1.2 to 7.2] and 2.4 [95 percent confidence interval, 1.1 to 5.3], respectively). The corresponding odds ratios were 1.1 (95 percent confidence interval, 0.5 to 2.6) and 0.6 (95 percent confidence interval, 0.3 to 1.3) in non-mite-sensitized subjects. Irrespective of mite sensitization, GDF was independently associated with eczema but not rhinitis.

"These novel findings suggest that components of GDF may act as adjuvants that facilitate sensitization to mites, and that mite-sensitized individuals may be especially susceptible to inhalant occupational exposures," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »